Anlotinib (Fukewei)
Jump to navigation
Jump to search
Mechanism of action
From the NCI Drug Dictionary: The hydrochloride salt form of catequentinib, a receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities. Upon administration, catequentinib targets multiple RTKs, including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3). This agent may both inhibit angiogenesis and halt tumor cell growth.
Diseases for which it is used
History of changes in NMPA indication
- 2018-05-08: Approved as a treatment for patients with advanced non-small cell lung cancer (NSCLC) who have progressed after treatment with two or more lines of prior systemic chemotherapy. (Based on ALTER 0303)
Also known as
- Code name: AL-3818
- Generic name: catequentinib
- Brand name: Fukewei